MDNA Moves Into Liquid Biopsy Market With New Prostate Cancer Test

Dec 02, 2016

|

Premium

NEW YORK (GenomeWeb) – Mitochondrial DNA diagnostics firm MDNA Life Sciences announced the launch of its first noninvasive blood-based cancer test this week, with Phi Life Sciences as the assay's first US distributor.

Though the company got its start developing assays for analysis of tissue samples, researchers have more recently found that the firm's mitochondrial DNA-based approach is similarly sensitive when applied to blood samples. Based on this, the company has now shifted its focus to the liquid biopsy space.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

Featured White Papers

A High-Performance Solution Combining CleanPlex OncoZoom Cancer Hotspot Panel and SOPHiA AI for Rapid Characterization of Somatic Mutations

Benchmarking of the Microsart AMP Mycoplasma Kit with Products of Two Other Suppliers

Type 1 Interferon Gene Expression Analysis: Precision Medicine in Lupus

Oct

24

Featured Webinar

Designing, Decoding & Delivering on Genetic Testing for Inherited Disease at Versiti

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

Nov

14

Featured Webinar

High-Performance Variant Detection in Somatic Cancer Testing with an Integrated NGS Solution

This webinar will discuss some of the issues laboratories face when transitioning to next-generation sequencing, and the key features to be considered for a successful implementation in routine testing.

Dec

02

Featured Webinar

Comprehensive Profiling of Myeloid Malignancies with Reliable Detection of FLT3 and CEBPA

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Menu